By Ben Fidler | Published September 25, 2026
The biopharmaceutical sector continues to demonstrate rapid evolution, marked by high-stakes licensing deals, complex courtroom battles, and significant regulatory milestones. As of late September 2026, the industry is grappling with the implications of a major infusion of long-acting drug delivery technology, the ongoing uncertainty surrounding Alzheimer’s drug development, and the shifting competitive dynamics in the multi-billion-dollar diabetes and oncology markets.
Main Facts: A Convergence of Innovation and Litigation
This week’s industry developments highlight a strategic pivot toward convenience and long-term therapeutic management. Novo Nordisk has made a bold play to secure its dominance in the cardiometabolic space by partnering with Swedish biotech Nanexa to access “PharmaShell” technology. Meanwhile, the regulatory front saw significant movement, with the FDA greenlighting a new once-weekly insulin option from Eli Lilly, signaling a direct challenge to Novo’s recently approved Awiqli.
In the legal arena, a long-simmering dispute between Nektar Therapeutics and Eli Lilly reached a verdict, though the outcome underscored the high risks associated with collaborative drug development. Furthermore, Merck & Co. continues to extract maximum value from its pipeline, securing yet another indication for its blockbuster kidney cancer drug, Welireg.
Chronology of Key Developments
- 2019: Merck & Co. acquires Peloton Therapeutics, gaining the rights to the drug candidate that would eventually become Welireg.
- 2023: Nektar Therapeutics files a lawsuit against Eli Lilly, alleging that the latter intentionally undermined their collaborative autoimmune project following Lilly’s acquisition of a competing therapy.
- March 2026: The FDA grants approval to Novo Nordisk’s Awiqli, the first once-weekly basal insulin treatment for adults with Type 2 diabetes.
- September 24, 2026: A California federal jury returns a verdict in the Nektar vs. Lilly litigation, awarding Nektar $90 million in damages.
- September 25, 2026: The FDA approves Eli Lilly’s once-weekly insulin, Onswik, and expands the label for Merck’s Welireg to treat relapsed kidney cancer.
- September 25, 2026: Novo Nordisk announces a global license and collaboration agreement with Nanexa worth up to $1.32 billion.
Supporting Data: The Economics of Innovation
The Novo-Nanexa Deal
Novo Nordisk’s agreement with Nanexa is a testament to the industry’s obsession with patient adherence. By licensing the "PharmaShell" technology, Novo aims to develop formulations for obesity and Type 2 diabetes that require administration as infrequently as once monthly or even quarterly. The deal structure—up to 1.165 billion euros ($1.32 billion)—reflects the premium placed on drug delivery innovation. With 615 million euros tied to upfront payments and near-term milestones, Nanexa gains significant financial runway, while Novo secures a potential "moat" around its flagship cardiometabolic portfolio.
The Nektar-Lilly Verdict
The $90 million award granted to Nektar Therapeutics by a federal jury is a fraction of the $1 billion the company sought in its breach-of-contract lawsuit. The litigation centered on whether Lilly prioritized its own internally developed assets over the joint project with Nektar after a strategic acquisition. While Nektar secured a moral and legal win, the disparity between the requested and awarded damages highlights the difficulty of quantifying "lost potential" in collaborative R&D agreements.
Acadia’s Alzheimer’s Gamble
Acadia Pharmaceuticals remains committed to its experimental Alzheimer’s drug, remlifanserin, despite a "near-miss" in Phase 2 clinical trials. The drug failed to hit the threshold for statistical significance in treating hallucinations and delusions associated with Alzheimer’s disease psychosis. Despite the setback, Acadia is pushing forward into Phase 3, citing a favorable safety profile. The financial market reaction was swift, with shares dropping by double digits, reflecting investor skepticism regarding the efficacy data provided thus far.
Official Responses and Expert Analysis
The industry’s reaction to these developments is mixed. Regarding the Acadia trial, analysts remain divided. Stifel analyst Paul Matteis noted, “The debate is going to be whether there is still a chance that the drug will succeed in Phase 3 studies. In our view, there is still a chance.” However, he tempered this optimism by noting that the mid-stage trial was robustly designed, making the modest efficacy findings particularly concerning.
Regarding the FDA’s approval of Onswik, Eli Lilly is positioning the drug as a significant advancement in convenience. "Once-weekly administration has the potential to fundamentally change the treatment landscape for Type 2 diabetes patients who struggle with the burden of daily injections," said a spokesperson for the company. This follows the regulatory precedent set by the approval of Novo’s Awiqli earlier this year, setting the stage for a fierce marketing battle in the weekly insulin segment.
Implications for the Future
The Battle for Adherence
The push toward longer-acting injectables, exemplified by the Novo-Nanexa partnership, suggests that the future of chronic disease management lies in "set-it-and-forget-it" therapies. By reducing the frequency of administration, pharmaceutical companies hope to improve patient compliance, which historically remains low for daily treatments. This shift will likely place pressure on traditional daily medication providers to innovate or face obsolescence.
Regulatory Expansion and Competitive Pressure
The expansion of Merck’s Welireg into the relapsed kidney cancer space underscores the efficacy of "indication-seeking"—a strategy where companies maximize the revenue potential of a drug by testing it across multiple disease stages and patient subsets. For Merck, Welireg has already proven its worth, generating $470 million in first-half sales, and the latest FDA nod provides a clear runway for continued growth.
The Shadow of Litigation
The Nektar-Lilly verdict serves as a cautionary tale for the industry. As big pharma companies increasingly rely on external innovation from smaller biotechs, the legal frameworks governing these collaborations will face increased scrutiny. The jury’s decision suggests that while courts are willing to protect smaller innovators, the bar for proving damages related to "undermined" research remains exceptionally high.
Conclusion: A Market in Flux
The events of the past week reflect a broader trend: the biopharma sector is moving toward a more specialized, technology-driven model where the delivery mechanism is as critical as the molecule itself. As companies like Novo Nordisk and Eli Lilly compete for dominance in the diabetes and obesity markets, and as firms like Merck and Acadia navigate the complexities of oncology and neurology, the industry will continue to experience volatility. Investors and stakeholders should expect that while innovation remains the primary driver of value, the ability to successfully navigate the regulatory and legal minefields will be the true determinant of long-term success.
As we look toward the remainder of 2026, the focus will undoubtedly shift to how these new therapies perform in the "real world" outside of clinical trials and how the impending post-trial proceedings in the Nektar case might set a precedent for future collaborative disputes. The biopharma industry is not merely selling drugs; it is selling the future of patient experience, and the race to refine that experience has never been more competitive.
